Literature DB >> 7505286

Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).

M O Savage1, W F Blum, M B Ranke, M C Postel-Vinay, A M Cotterill, K Hall, P G Chatelain, M A Preece, R G Rosenfeld.   

Abstract

Twenty-seven patients with GH insensitivity were identified from 44 possible cases, using a scoring system based on height standard deviation score (SDS), basal GH, insulin-like growth factor-I (IGF-I), IGF-I response to IGF-I generation test, and GH-binding protein (GH-BP) determinations. The 27 cases were from 8 European countries and Australia. Clinical features were as follows: age 2.8-22.6 yr; 12 male, 15 female, 19 prepubertal. Birth weight was median -0.72 SDS (1.75(-)-3.29) and birth length, median -1.59 SDS (0.63(-)-3.63). Hypoglycemia had been documented in 33% of the cases, and micropenis was present in 58% of the males. At assessment, height was median -6.1 SDS (-3.8(-)-10.2), weight was median -3.2 SDS (-0.1 to -5.2), and percentage weight for height, median 111.3 (72-271). Puberty was absent in 2 boys aged 15 yr and in 3 girls aged 13 yr. Bone age was delayed in 19 of the 27 patients. Endocrine investigations showed basal serum GH median 17 micrograms/L (0.5-79), IGF-I values less than 5th percentile, and all except 2, age less than 8 yr, less than 0.1 percentile for age. Percentage increment of IGF-I during IGF-I generation test (hGH 0.1 U/kg body weight daily x 4) did not exceed twice the intraassay coefficient of variation, being less than 0.1 percentile for age. IGF-II was median 135.0 micrograms/L (62-232), all values being less than 5th percentile for age. Insulin-like growth factor binding protein-3 (IGFBP-3) values were median 0.53 mg/L (0.10-1.17 mg/L), all being less than 5th percentile for age. IGFBP-3 values after hGH remained less than 5th percentile. IGFBP-1 values showed the normal fall with age, some being above the normal range; IGFBP-2 values were normal. There was a positive correlation between height SDS and IGF-II SDS (r = 0.66, P < 0.001) and IGFBP-3 (r = 0.64, P < 0.001). Specific binding of [125I]hGH to GH-BP was undetectable in 18 patients and extremely low (< or = 5.6%) in 2. GH-BP was normal (14.2-45.9% radioactivity) in 7 subjects, all female, demonstrating that normal GH-BP does not exclude GH insensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505286     DOI: 10.1210/jcem.77.6.7505286

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Growth hormone insensitivity: a widening diagnosis.

Authors:  R Bjarnason; M O Savage
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity.

Authors:  L A Metherell; S A Akker; P B Munroe; S J Rose; M Caulfield; M O Savage; S L Chew; A J Clark
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

Review 3.  Insulin-like growth factor (IGF)-I gene deletion.

Authors:  Cecilia Camacho-Hübner; Katie A Woods; Adrian J L Clark; Martin O Savage
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

4.  The child with micropenis.

Authors:  P S Menon; U A Khatwa
Journal:  Indian J Pediatr       Date:  2000-06       Impact factor: 1.967

5.  Correlation of Insulin-Like Growth Factor-I and -II Concentrations at Birth Measured by Mass Spectrometry and Growth from Birth to Two Months.

Authors:  Colin P Hawkes; Deirdre M Murray; Louise C Kenny; Mairead Kiely; Jonathan O'B Hourihane; Alan D Irvine; Zengru Wu; Yair Argon; Richard E Reitz; Michael J McPhaul; Adda Grimberg
Journal:  Horm Res Paediatr       Date:  2018-01-18       Impact factor: 2.852

Review 6.  Growth Hormone Deficiency: Health and Longevity.

Authors:  Manuel H Aguiar-Oliveira; Andrzej Bartke
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 7.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

8.  Divergent roles of growth factors in the GnRH regulation of puberty in mice.

Authors:  Sara A Divall; Tameeka R Williams; Sarah E Carver; Linda Koch; Jens C Brüning; C Ronald Kahn; Fredric Wondisford; Sally Radovick; Andrew Wolfe
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

9.  Long-term auxological and pubertal outcome of patients with hereditary insulin-like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin-like growth factor-I.

Authors:  M F Messina; T Arrigo; M Valenzise; L Ghizzoni; M Caruso-Nicoletti; S Zucchini; P Chiabotto; G Crisafulli; G Zirilli; F De Luca
Journal:  J Endocrinol Invest       Date:  2010-06-11       Impact factor: 4.256

Review 10.  Treatment of dwarfism with recombinant human insulin-like growth factor-1.

Authors:  Michael B Ranke; Joachim Wölfle; Dirk Schnabel; Markus Bettendorf
Journal:  Dtsch Arztebl Int       Date:  2009-10-23       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.